Compare Revvity Inc (RVTY) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vanguard International High Dividend Yield ETF — how do they compare? Revvity Inc trades at $154.18 (market cap $16.98B), while Vanguard International High Dividend Yield ETF trades at $100.66 (market cap $22.80B). The key difference: Vanguard International High Dividend Yield ETF is the larger of the two by market cap, and Revvity Inc pays a 0.18% dividend while Vanguard International High Dividend Yield ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 12 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| RVTY | VYMI | |
|---|---|---|
Market Cap | $16.98B | $22.80B |
Volume | 1,456,900 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $157.36 | $107.13 |
52-Week Low | $82.26 | $82.92 |
Typical Hold Time | 12 Days | 50 Days |
Enterprise Value | $19.30B | — |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
VYMI trades at $100.06, down 0.17% with bearish technical signals from moving averages. The ETF shows strong institutional interest with recent stake increases from Envestnet and Corient Private Wealth. Recent news highlights VYMI's 29% one-year return and 3.61% dividend yield, outperforming peers with lower fees. The fund's heavy financial sector exposure (43.6%) benefits from rising global interest rates.
VYMI presents a compelling international dividend growth opportunity with attractive valuation and income characteristics. Key risks include concentration in financials and sensitivity to global economic conditions. The ETF's low 0.07% expense ratio and strong historical performance support its appeal for income-focused investors seeking international diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
